1. Home
  2. CCS vs IDYA Comparison

CCS vs IDYA Comparison

Compare CCS & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCS
  • IDYA
  • Stock Information
  • Founded
  • CCS 2000
  • IDYA 2015
  • Country
  • CCS United States
  • IDYA United States
  • Employees
  • CCS N/A
  • IDYA N/A
  • Industry
  • CCS Homebuilding
  • IDYA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CCS Consumer Discretionary
  • IDYA Health Care
  • Exchange
  • CCS Nasdaq
  • IDYA Nasdaq
  • Market Cap
  • CCS 1.9B
  • IDYA 2.3B
  • IPO Year
  • CCS 2014
  • IDYA 2019
  • Fundamental
  • Price
  • CCS $63.13
  • IDYA $32.84
  • Analyst Decision
  • CCS Buy
  • IDYA Buy
  • Analyst Count
  • CCS 4
  • IDYA 17
  • Target Price
  • CCS $80.75
  • IDYA $48.20
  • AVG Volume (30 Days)
  • CCS 351.6K
  • IDYA 1.3M
  • Earning Date
  • CCS 10-22-2025
  • IDYA 11-04-2025
  • Dividend Yield
  • CCS 1.82%
  • IDYA N/A
  • EPS Growth
  • CCS N/A
  • IDYA N/A
  • EPS
  • CCS 6.93
  • IDYA N/A
  • Revenue
  • CCS $4,157,669,000.00
  • IDYA $7,000,000.00
  • Revenue This Year
  • CCS N/A
  • IDYA $90.17
  • Revenue Next Year
  • CCS $10.71
  • IDYA $219.42
  • P/E Ratio
  • CCS $9.20
  • IDYA N/A
  • Revenue Growth
  • CCS N/A
  • IDYA N/A
  • 52 Week Low
  • CCS $50.42
  • IDYA $13.45
  • 52 Week High
  • CCS $95.76
  • IDYA $33.64
  • Technical
  • Relative Strength Index (RSI)
  • CCS 53.06
  • IDYA 71.22
  • Support Level
  • CCS $61.35
  • IDYA $28.17
  • Resistance Level
  • CCS $64.46
  • IDYA $33.64
  • Average True Range (ATR)
  • CCS 2.13
  • IDYA 1.62
  • MACD
  • CCS 0.56
  • IDYA 0.44
  • Stochastic Oscillator
  • CCS 67.14
  • IDYA 89.46

About CCS Century Communities Inc.

Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: